Apellis APL2-303 DERBY
Posted by: Georgia Retina in
Research Title: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Sponsor: Apellis Pharmaceuticals, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to…
Read More